Pulmonx (NASDAQ:LUNG) General Counsel David Aaron Lehman Sells 9,769 Shares

Key Points

• David Aaron Lehman, General Counsel of Pulmonx Corporation, sold 9,769 shares at an average price of $1.60, resulting in a total value of $15,630.40, and a 3.58% decrease in his ownership.
• Pulmonx's stock is currently trading at $1.66 with a 1-year low of $1.47 and a high of $9.37, while the company has a market cap of $67.65 million.
• Analysts have adjusted their ratings and price targets for Pulmonx, with Wells Fargo lowering its price objective from $6.00 to $3.00, indicating a cautious outlook for the stock.

Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) General Counsel David Aaron Lehman sold 9,769 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $1.60, for a total value of $15,630.40. Following the completion of the transaction, the general counsel owned 263,270 shares of the company's stock, valued at approximately $421,232. The trade was a 3.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pulmonx Stock Performance

Shares of LUNG remained flat at $1.74 on Friday. The stock had a trading volume of 304,193 shares, compared to its average volume of 653,362. The firm has a market capitalization of $70.91 million, a price-to-earnings ratio of -1.22 and a beta of 0.43. The company has a quick ratio of 4.63, a current ratio of 5.35 and a debt-to-equity ratio of 0.54. The company's 50-day moving average price is $2.25 and its 200-day moving average price is $4.10. Pulmonx Corporation has a 52 week low of $1.47 and a 52 week high of $9.37.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. The company had revenue of $23.86 million during the quarter, compared to analysts' expectations of $23.46 million. Pulmonx had a negative return on equity of 69.76% and a negative net margin of 62.88%. Pulmonx has set its FY 2025 guidance at EPS. On average, analysts expect that Pulmonx Corporation will post -1.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. ProShare Advisors LLC purchased a new position in shares of Pulmonx in the fourth quarter worth $72,000. Vontobel Holding Ltd. purchased a new position in shares of Pulmonx in the first quarter worth $82,000. Millennium Management LLC raised its stake in shares of Pulmonx by 26.6% in the fourth quarter. Millennium Management LLC now owns 183,069 shares of the company's stock worth $1,243,000 after purchasing an additional 38,425 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Pulmonx by 17.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 408,022 shares of the company's stock worth $2,770,000 after purchasing an additional 60,489 shares during the last quarter. Finally, Stifel Financial Corp purchased a new position in shares of Pulmonx in the fourth quarter worth $81,000. Hedge funds and other institutional investors own 91.04% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on LUNG. Wall Street Zen upgraded Pulmonx from a "sell" rating to a "hold" rating in a research note on Saturday, August 30th. Piper Sandler lowered Pulmonx from an "overweight" rating to a "neutral" rating and reduced their price objective for the company from $9.00 to $2.50 in a research report on Thursday, July 31st. Stifel Nicolaus reduced their price objective on Pulmonx from $16.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday, July 31st. Lake Street Capital reduced their price objective on Pulmonx from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Thursday, July 31st. Finally, Wells Fargo & Company reduced their price objective on Pulmonx from $6.00 to $3.00 and set an "equal weight" rating for the company in a research report on Friday, August 1st. Five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.66.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.